An impressive 156 countries — 64 of them high-income nations including Australia and Japan — have already signed on to the initiative, called the COVID-19 Vaccines Global Access (COVAX) Facility, which hopes to distribute 2 billion vaccine doses by the end of 2021, Ars Technica reports. Dozens more are expected to join in the coming days, but notable absences include the U.S., China, and Russia.
Without broader support, COVAX may not get the funding it needs to succeed. The plan is to pool resources to support nine experimental vaccines that are already underway, and then purchase doses once it’s ready. So far, the initiative has raised just $3 billion of the $35 billion it needs.
China and Russia have already begun distributing experimental vaccines, even before clinical trials designed to test their safety and efficacy were completed, and U.S. President Trump has expressed interest in doing the same.